Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday, July 13th. The firm currently has a $49.00 price objective on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 16.39% from the stock’s previous close.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Several other research analysts also recently commented on SUPN. Piper Jaffray Companies upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $30.00 to $44.00 in a report on Thursday, June 1st. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Cowen and Company raised their price target on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, May 11th. Jefferies Group LLC restated a “buy” rating and issued a $35.00 price target on shares of Supernus Pharmaceuticals in a research report on Tuesday, April 11th. Finally, Stifel Nicolaus raised their price target on shares of Supernus Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, April 3rd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $48.43.

Supernus Pharmaceuticals (SUPN) traded up 2.56% during midday trading on Thursday, hitting $42.10. The company had a trading volume of 466,267 shares. The stock has a market cap of $2.13 billion, a PE ratio of 21.25 and a beta of 1.31. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $44.95. The stock’s 50-day moving average price is $42.27 and its 200-day moving average price is $33.33.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.24 by $0.08. The firm had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. On average, equities research analysts expect that Supernus Pharmaceuticals will post $1.00 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Upgraded to “Buy” by Zacks Investment Research” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/07/supernus-pharmaceuticals-inc-nasdaqsupn-stock-rating-upgraded-by-zacks-investment-research-updated-updated-updated.html.

In other news, VP Padmanabh P. Bhatt sold 2,500 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $35.90, for a total transaction of $89,750.00. Following the sale, the vice president now directly owns 37,500 shares in the company, valued at approximately $1,346,250. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $34.90, for a total transaction of $191,950.00. Following the completion of the transaction, the vice president now owns 43,887 shares in the company, valued at $1,531,656.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,291 shares of company stock worth $962,766. 6.70% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. raised its position in Supernus Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after buying an additional 517 shares during the period. State Board of Administration of Florida Retirement System raised its position in Supernus Pharmaceuticals by 2.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 23,677 shares of the specialty pharmaceutical company’s stock worth $1,020,000 after buying an additional 671 shares during the period. Chartwell Investment Partners LLC purchased a new position in Supernus Pharmaceuticals during the second quarter worth approximately $2,124,000. KBC Group NV purchased a new position in Supernus Pharmaceuticals during the second quarter worth approximately $1,222,000. Finally, Legal & General Group Plc raised its position in Supernus Pharmaceuticals by 9.5% in the second quarter. Legal & General Group Plc now owns 90,087 shares of the specialty pharmaceutical company’s stock worth $3,881,000 after buying an additional 7,815 shares during the period. Hedge funds and other institutional investors own 94.39% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.